Abbott Products Operations AG Allschwil, Switzerland.
Front Neurol. 2013 May 10;4:48. doi: 10.3389/fneur.2013.00048. eCollection 2013.
Despite being a common disease, data on vertigo management in a real-world setting are scarce.
To provide information on the vertigo and its management in a real-world setting.
Data were collected from 4,294 patients with vertigo in 13 countries over 28 months via a multi-national, non-interventional observational study (the so-called REVERT registry). Data included medical history and details of anti-vertigo therapy. "Clinical global impression" (CGI) of severity (CGI-S) was assessed at baseline (V1) and then at 6 months follow-up (V2) along with CGI change (CGI-C). All variables were analyzed descriptively.
The majority of patients were female, >40 years of age, and almost half had co-morbid cardio-vascular disease. Diagnoses were split into four categories: 37.2% "other vertigo of peripheral vestibular origin," 26.9% benign paroxysmal positional vertigo (BPPV), 20.5% "peripheral vestibular vertigo of unknown origin," and 15.4% Ménière's disease (MD). Betahistine was the most commonly prescribed therapy prior to and after enrollment, and was followed by piracetam, ginkgo biloba, and diuretics. MD had the highest proportion of betahistine treated patients. Almost half of patients were "moderately ill" at V1 based on CGI-S. At V2, patient distribution moved toward "less severe illness" (91.0% improved). The greatest improvements were in the more severely ill, and those with BPPV or "other vertigo of peripheral origin."
There was a reduction in illness severity over the course of the study, some of which is likely to be due to pharmacological intervention. Further studies are needed to confirm these results.
尽管眩晕是一种常见疾病，但在真实世界环境中关于其管理的数据却很少。
提供真实世界环境中眩晕及其管理的信息。
通过一项多国家、非干预性观察研究（所谓的 REVERT 登记研究），在 28 个月内从 13 个国家的 4294 例眩晕患者中收集数据。数据包括病史和抗眩晕治疗详情。在基线（V1）和 6 个月随访（V2）时评估“临床总体印象”（CGI）严重程度（CGI-S），并评估 CGI 变化（CGI-C）。所有变量均进行描述性分析。
大多数患者为女性，年龄＞40 岁，近一半合并心血管疾病。诊断分为四类：37.2%“其他外周前庭源性眩晕”、26.9%良性阵发性位置性眩晕（BPPV）、20.5%“不明原因外周前庭眩晕”和 15.4%梅尼埃病（MD）。倍他司汀在入组前后是最常开的治疗药物，其次是吡拉西坦、银杏叶和利尿剂。MD 中使用倍他司汀治疗的患者比例最高。根据 CGI-S，近一半的患者在 V1 时“病情中度”。在 V2 时，患者分布向“较轻疾病”转移（91.0%改善）。病情较重的患者和 BPPV 或“其他外周前庭源性眩晕”患者的改善程度最大。
在研究过程中，疾病严重程度有所下降，部分原因可能是药物干预。需要进一步的研究来证实这些结果。
